Compare Apollo Global Management Ord Shs (APO) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apollo Global Management Ord Shs vs BioNTech SE - ADR — how do they compare? Apollo Global Management Ord Shs trades at $138.82 (market cap $82.84B), while BioNTech SE - ADR trades at $93.42 (market cap $23.31B). The key difference: Apollo Global Management Ord Shs is far larger — about 3.6× BioNTech SE - ADR's market cap, and Apollo Global Management Ord Shs pays a 1.6% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| APO | BNTX | |
|---|---|---|
Market Cap | $82.84B | $23.31B |
Sector | Financials | Health |
52-Week High | $152.70 | $119.34 |
52-Week Low | $100.30 | $83.89 |
Enterprise Value | -$168.65B | $6.60B |
Dividend Yield | 1.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $137.75, up 4.34% today, near its 52-week high. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Q2 2026 earnings missed estimates at $2.11 per share versus $2.16 expected, but revenue growth remains robust with record fee-related earnings. Recent news highlights strategic AI infrastructure deals and a $2.6 billion financing agreement with Yankee Global Enterprises.
Outlook is positive with an 82% analyst buy rating and $151.50 consensus price target, implying 10% upside. Risks include expense growth impacting net margins and competitive pressures in asset management. The company's strong capital formation and perpetual capital base support long-term growth, but investors should monitor execution on AI initiatives and interest rate sensitivity.
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
